Brief: Ocumension Therapeutics Entered Series Of Cooperation Arrangements With Viatris Pharmaceuticals
01/03/2022 10:47
March 1 (Reuters) - Ocumension Therapeutics 1477.HK :
* ENTERED SERIES OF COOPERATION ARRANGEMENTS WITH VIATRIS
PHARMACEUTICALS
* UNDER ARRANGEMENTS, GROUP TO PROMOTE AND MARKET IN
HOSPITALS
NATIONWIDE IN CHINA TWO OPHTHALMIC DRUGS OF VIATRIS
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application